Detalles de la búsqueda
1.
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
Hepatology
; 77(5): 1746-1756, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36633913
2.
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
J Med Virol
; 95(1): e28210, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36222204
3.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Invest New Drugs
; 41(2): 340-349, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995548
4.
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hepatol Res
; 53(1): 61-71, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36070216
5.
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
J Viral Hepat
; 29(7): 551-558, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35548866
6.
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Invest New Drugs
; 40(6): 1290-1297, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152108
7.
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Clin Infect Dis
; 73(9): e3349-e3354, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33544129
8.
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
J Med Virol
; 93(11): 6247-6256, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34170517
9.
Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Hepatol Res
; 49(3): 264-270, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171740
10.
Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis.
Hepatol Res
; 48(9): 746-756, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29480939
11.
Tumor invasion to the arteries feeding the gallbladder as a novel risk factor for cholecystitis after metallic stent placement in distal malignant biliary obstruction.
Dig Endosc
; 30(3): 380-387, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29181859
12.
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.
JGH Open
; 8(4): e13068, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38681824
13.
Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.
JGH Open
; 7(6): 424-430, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37359109
14.
[A case of endocrine carcinoma of the cecum treated with CDDP/VP-16].
Gan To Kagaku Ryoho
; 39(8): 1255-8, 2012 Aug.
Artículo
en Japonés
| MEDLINE | ID: mdl-22902453
15.
Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection.
JGH Open
; 6(5): 344-352, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35601120
16.
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.
Cancers (Basel)
; 14(12)2022 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35740647
17.
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.
Hepatol Commun
; 6(3): 461-472, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34676692
18.
A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.
JGH Open
; 6(1): 20-28, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35071784
19.
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.
JGH Open
; 6(7): 487-495, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35822118
20.
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Cancers (Basel)
; 13(11)2021 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34073396